Mepact

Mifamurtide, the active ingredient in Mepact, is an immunostimulant presented as a 1 mg lyophilized powder for intravenous use. It is indicated for high‑grade non‑metastatic osteosarcoma after complete surgical resection in pediatric and young adult patients.

GNH USA supplies Mepact as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Mepact is used as part of the postoperative treatment regimen for high‑grade osteosarcoma, targeting the disease’s immune‑mediated pathways. - High‑grade non‑metastatic osteosarcoma: improves event‑free survival when added to standard postoperative chemotherapy after complete surgical resection. - Adjunctive chemotherapy: administered alongside multi‑agent chemotherapy to enhance immune‑mediated tumor control. - Pediatric and young adult patients: approved for use in patients up to 30 years of age following surgery.

Mepact may cause a range of adverse reactions, most of which are related to immune activation and infusion.

Common Side Effects: - Fever or chills - Nausea and vomiting - Fatigue or malaise - Headache - Hypotension during infusion - Injection‑site pain or erythema

Serious or Rare Side Effects: - Severe hypersensitivity or anaphylaxis - Cytokine release syndrome - Hepatic enzyme elevation - Acute respiratory distress - Severe hypotension requiring intervention - Thromboembolic events

Mepact requires careful monitoring due to its immunostimulatory properties. - Monitor vital signs: observe blood pressure, temperature, and heart rate during and after infusion. - Assess for hypersensitivity: discontinue infusion if severe allergic reactions occur. - Evaluate liver function: check hepatic enzymes before each treatment cycle. - Use with caution in immunocompromised patients: increased infection risk. - Avoid in patients with active uncontrolled infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mepact can interact with other agents that modify immune function or hemodynamics.

Major Interactions (Avoid): - Live vaccines: concurrent use may alter vaccine efficacy or increase adverse events. - Potent immunosuppressants (e.g., high‑dose steroids, calcineurin inhibitors): may diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Anticoagulants: cytokine release may affect coagulation parameters. - Other immunostimulants: additive risk of cytokine‑related toxicity. - Drugs affecting hepatic metabolism: monitor liver enzymes as Mepact may influence hepatic function.